Neurovine uses cutting-edge technology, including AI and machine learning, to deliver personalized treatment plans for brain recovery.

“We envision a world in which brain health is visible and accessible - empowering everyone to reach their full potential for health and well-being.”

-Ashleigh Kennedy, CEO

Investment Highlights

Neurovine is the "Fitbit of the brain" with an evidence-based approach to support mental health and brain recovery.

The global wearable technology market was valued at $61.3 billion USD in 2022 and is expected to expand at a CAGR of 14.6% from 2023 to 2030.
Neurovine’s proprietary technology leads to 40% faster recovery for concussion patients compared to standard treatment.
Awarded the ‘Next Big Business Award’ from Ottawa Business Journal and ranked as one of the most promising health startups in the world on the CB Insights 150 list.
Neurovine’s unique digital prescription therapeutic treatment has completed clinical trial testing in the Digital Health program at the Elizabeth Bruyère Research Institute with impressive results and is ready for commercialization.
The company has built strategic partnerships with well-known organizations, including the UFC, establishing itself as a thought leader in the industry.
Neurovine’s leadership team has over 20+ years of practical neuroscience experience and has built a portfolio of dependable IP.

With over $1 million already raised from prominent investors and angel groups, such as Backbone Angels and Leva Capital, Neurovine is opening up the remainder of its $1.5 million round to all Canadians.

About Neurovine

Making brain health accessible and affordable.

Founded in 2019, Neurovine is an evidence-based brain health solution created by doctors for patients and their care teams.

14233 about neurovine 20230210050812596

In her work as a neuroscientist, our CEO & Co-Founder, Dr. Ashleigh Kennedy saw that when individuals were sent home after a traumatic brain injury or stroke, their recovery slowed and their mental health suffered significantly.

Meanwhile, as a family physician with a special interest in brain health, our Co-Founder & Chief Medical Officer, Dr. Matthew Kennedy, was routinely frustrated by the lack of data available to support his patients recovering from brain injury, illness, and burnout.

They set out on a mission to make brain health visible and actionable for patients and their care team so they can receive early, personalized therapy.

Problem

Brain health is invisible and costly

Brain recovery is a major challenge facing individuals and the healthcare industry.

14233 problem 5 with sources 20230210224538532

Brain health is subjective

Diagnosis and treatment of brain illness and injury is reliant on subjective assessments and patient reports.

Treatment plans are vague

When a concussion is diagnosed, it is very difficult to understand the cause of symptoms. This leads to vague treatment plans that are not tailored to the individual’s needs.

Brain recovery is expensive

Post-concussion syndrome (PCS) patients spend $8,000 - $10,000 on treatment and take ~ 55 days to get back to work or school which results in Blue Cross Blue Shield spending $10B/year on concussions.*

Mental health suffers during recovery

65% of people with a concussion experienced symptoms of depression and anxiety after injury, making it difficult to return to work.**

Sources: *BCBS, The Health of America Report, (2015), **Whelan-Goodinson et al. J Head Trauma Rehabil. (2009) 24:324–32.

Solution

Revolutionizing brain recovery.

The Neurovine platform combines EEG data measured by the Sensorband© with patient-logged mental and behavioral health information to provide personalized data-driven brain health therapies delivered directly to the patient.

14233 solution 20230210051255646

Therapy is targeted

Personalized, targeted therapy, unique to the individual's brain. With AI, a gamified onboarding process tailors algorithms and applications to the patient's specific brain needs.

Mental health is supported

Comprehensive mental health support that empowers the patient with data-driven therapy, and personalized guided meditation modules to support complete recovery.

Recovery is affordable

Affordable recovery by diagnosing and treating the issue early to prevent long-term symptoms.

The technology was first used to support recovery from a concussion but it can also support patients returning to work and school, after stress leave and burnout, as well as after experiencing long-haul COVID19.

Product

40% faster recovery compared to standard care.

Neurovine's Sensorband© and app work together to promote activity and cognitive pacing.

A clinical trial was completed in 2022 to show the efficacy of the technology which concluded that 60-day intervention with tech resulted in 40% faster recovery compared to standard care. This is in addition to the improvements seen in depression, anxiety, and other perceived symptoms.

14233 product 20230210051723148

Sources: Kennedy et al. 2022 Big Sky Conference, and Kennedy et al. 2023 Bruyère Research Symposium.

Our comfortable EEG Sensorband is equipped with a heart rate monitor and cloud-based analytics software that delivers real-time cognitive overexertion alerts and personalized guided meditations.

The technology provides visibility and accessibility to brain health data, allowing individuals to engage in exercise with confidence and prevent cognitive fatigue.

14233 product 2a 20230210052125398

The easy-to-use mobile app interface is optimized for accessibility and user experience, with modifications for limited text, full dark mode, and intuitive navigation. Move with confidence, enhance cognitive performance, and promote better brain health with the Neurovine Solution. Today the full solution is available as a wellness device, however new features are also being tested with patients this spring through a Health Canada Investigational Testing Authorization.

14233 product 3 20230210052247736

Neurovine is currently developing an AI-powered clinical decision support system that will support prognosis and tailor recovery programs to clinicians and patients.

When complete, this clinical decision support system will be registered as a software-as-a-medical device with regulatory bodies in Canada and the USA. Neurovine owns all the intellectual property and has built a significant US-based patent portfolio around the AI algorithms, the software architecture, and the EEG Sensorband©.

How It Works

The science behind the application.

When a brain injury, like concussion, is diagnosed, a patient uses the proprietary Neurovine Sensorband© and mobile application to perform a gamified assessment.

Step 1: The app uses the Neurovine Sensorband© and a gamified assessment process to test cognitive function and mental health. The assessment, called "Get Set," involves a series of games that measure memory, executive function, and reaction. EEG is recorded during this process and mental health is assessed using gold standard questionnaires to provide a complete understanding of the patient's brain health.

14233 how it works 1 20230210052725128

Step 2: Based on the results of the assessment, 3 specific recovery modules are recommended to the patient including Move, Think and Restore. EEG data from the assessment is used to personalize algorithms and modules.

Move gets patients active within the right heart rate zone while tracking their progress and allowing them to log symptoms, effectively speeding concussion recovery.

Think supports cognitive pacing and provides a graduated return to school or work plan that uses your brain activity to warn you before you overexert.

Restore allows patients to access personalized guided meditations to help restore their mental energy upon receiving a brain break alert.

14233 how it works 2 20230210052942465

Market Opportunity

The global concussion market is growing.

The $36 billion global concussion market is estimated to grow at a CAGR of 7.5%. Neurovine is focusing specifically on the North American market which is valued at $3.4 billion.

14233 market 20230210054047956

With the company’s focus on employers, such as professional sports clubs and military organizations, this presents a $500 million market opportunity.

14233 market 1 20230210054255877

According to Grand View Research, the global wearable technology market was valued at $61.3 billion USD in 2022 and is expected to expand at a CAGR of 14.6% from 2023 to 2030. The increasing adoption of smart wearable technology products among consumers is driving industry growth.

Business Model

Enterprise, B2B, and starter Solutions.

Neurovine’s business model focuses on B2B through distribution partners. This includes an annual license delivered to patients through an employer or team organization.

The sports league and players association work as a channel to reach individual sports teams. On the employer side (including hospitals and medical clinics), Neurovine is working with employee assistance programs to distribute the Neurovine solution.

14233 business model 20230210054512658

Neurovine offers three pricing plans for its enterprise, B2B, and business clients: $100K/year for the enterprise solution, $50K/year for the business solution, and $15K/year for the starter package.

The enterprise solution is designed for sports leagues and large organizations, while the business solution is designed for organizations up to 100 people. The starter package is for small organizations or youth teams.

14233 bus model partners 20230210054635637

The EEG Sensorbands and access to the Neurovine Compass are included in each package, with varying quantities based on the plan chosen.

The company's sales pipeline primarily comprises hospitals, employers, and employee assistance programs, with a focus on mental health and well-being.

Traction

The efficacy and growth of the Neurovine platform.

The Neurovine platform has demonstrated efficacy for concussion and burnout recovery through its clinical trial. In Q1 of 2023, the controlled release with 2 organizations generated $81K in revenue.

14233 industry partners 20230224204126645

The plan for scaling in 2024 is through partnerships with independent employer insurance programs and American payors.

Press & Features

14233 press features 20230210055051601

“For the first time, the ‘invisible’ impact of head injury is being made visible, with patients now having the information that could protect their brain health and future wellbeing at their fingertips.”

Recognition & Awards

14233 awards 20230210055231324

Testimonials

“Using this technology made it 100% different this time from my first recovery.”

Neurovine aims to revolutionize brain health by providing innovative solutions for patients and their care teams.

Our technology is targeted and uniquely positioned as a digital prescription therapy designed to walk alongside the patient and support clinicians on the path to recovery.

Other similar solutions either exist in the diagnostic space or are stationary, clinic-based products not designed for accessible ease of use by patients.

14233 testimonials 20230210055433482

Our technology is designed and aimed for concussion recovery and at supporting individuals returning from stress leave, burnout, and long-haul COVID-19. By targeting clinics as a B2B model, Neurovine strives to improve patient outcomes and optimize brain function.

Marketing & Sales

Building partnerships and thought leadership.

Neurovine has established itself as a thought leader in the brain health and tech industry through its marketing strategy.

The company supports those suffering from brain injuries through strategic partnerships with well-known sports and military organizations.

The Neurovine marketing team aims to foster company growth by establishing these partnerships, targeting specific markets through SEO, blog posts, podcasts, and articles, and partnering with key distribution partners. These efforts aim to rapidly scale the company in 2023 and 2024.

14233 tv partners 20230210055706532

Competition

Neurovine's unique positioning.

Neurovine is uniquely positioned as a digital prescription therapeutic. Other solutions available are either in the diagnostic space or are not designed to walk alongside the patient on their path to recovery.

By engaging and empowering the patient, Neurovine provides an early, accessible, and targeted data-driven concussion recovery solution. Our focus is getting concussed individuals back to school, sports, work, and life safely and efficiently.

14233 competition 1 20230210055830134

Neurovine has a diverse and experienced leadership team consisting of serial entrepreneurs and individuals with over 20 years of practical neuroscience expertise.

This combination of medical insight, strategic vision, and execution track record gives Neurovine a competitive advantage in providing an early, accessible, and targeted concussion recovery solution.

The company has a defendable IP portfolio in software, firmware, and EEG processing, and has a privacy-first data architecture designed to comply with regulatory pathways.

Neurovine also has a structured data network that allows for monetizing user data sets anonymously, with over 5,000 data sets already available.

Investment Opportunity & Use of Funds

Funding our mission for brain health.

With nearly $1 million already raised from prominent investors and angel groups, Neurovine is opening up the remainder of its $1.5 million round to all Canadians.

This investment opportunity is a convertible note with a 30% discount in conjunction with a future round of equity financing. There is a 5% interest on the loan over three years.

Allocation of Funds:

1000 manufactured EEG Sensorbands©
Market adoption with distribution partners
Sales & customer service team members
Filling significant IP on data science

Notable investors in this round:

14233 neurovine campaign page v3 infographic style 2 20230210060050995

Industry Comparables & Exit Strategy

Healthtech acquisitions are on the rise.

In 2021, as the global economy roared back from COVID-19 shutdowns, the health technology mergers and acquisitions (M&A) market accelerated as the importance of healthtech became a top priority.

Notable Mergers & Acquisitions in health technology included:

14233 industry comps 20230210060324152

Sources: The New York Times, Forbes, MobiHealthNews

Investment continued in digital therapeutics and health technology into 2022 despite the overall market downturn.

- Cleerly, a company that uses AI to examine heart disease progression, landed a $223 million Series C

- Digital health and benefits management startup Transcarent raised $200 million in Series C funding

- HingeHealth, a virtual rehab platform raised $400 million in Series E funding

With the recent M&A activity combined with the accelerated adoption of AI digital therapies by patients, clinicians, and employers, Neurovine believes that acquisition is the most likely exit strategy.

14233 exits 20230210060614730

Note that there are generally three routes by which an investor may realize a return on their investment: (1) liquidity by a strategic sale to another company, (2) take the company public on a stock exchange (IPO or similar process), and (3) the company focuses on growth and distributes dividends to investors.

14233 thank you 20230210060735639

Thank You!

Offerings on the platform contain forward-looking information. Forward-looking information includes statements that may predict, forecast, indicate or imply future plans, intentions, levels of activity, results, performance or achievements, and involve known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of the issuer to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information.

Details of the offering can be found in the offering documents. This communication is for informational purposes only. Investing in crowdfunding and exempt market offerings has significant risk. Investors may not be able to resell quickly or at all. An exempt market security holder may also receive limited ongoing issuer information. You should invest only if you are prepared not to receive any return on your investment and/or lose your investment in its entirety. FFS will provide advice on the suitability of your investments made through its platform

Testimonials may not be representative of the experience of other customers or investors. These testimonials are no guarantee of future performance or success.